Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - urothelial


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.388
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.

Arlene Odelia Siefker-Radtke · Mayer Fishman · Arjun Vasant Balar · Giovanni Grignani · Adi Diab · Jianjun Gao · Mary Tagliaferri · Alison L. Hannah · Erin E. Karski · Jonathan Zalevsky · Ute Hoch · Ahsan Naqi Rizwan · Mehmet Asim Bilen ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.483
Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy.

Kyle Ericson · Lewis Thomas · Byron H. Lee ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS4593
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.

Christopher J. Hoimes · Jonathan E. Rosenberg · Daniel P. Petrylak · Anne-Sophie Carret · Amal Melhem-Bertrandt · Thomas W. Flaig ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.425
Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.

Andrea B. Apolo · John Allan Ellerton · Jeffrey R. Infante · Manish Agrawal · Michael S. Gordon · Raid Aljumaily · Carolyn D. Britten · Luc Dirix · Keun-Wook Lee · Matthew H. Taylor · Patrick Schöffski · Ding Wang · Alain Ravaud · Junyuan Xiong · Galit Rosen · James L. Gulley · Manish R. Patel ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.363
Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.

Petros Grivas · François Laliberté · Yunes Doleh · Cristi O’Connor · Mei Sheng Duh · Rahul Shenolikar ·

Medicine
PDF

Urine cytology is non-invasive, is a low-cost method, and has a high specificity but low sensitivity for low-grade urothelial tumors.

Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles [10.3390/ijms20040821]


PURPOSE This study sought to identify factors associated with survival of pT1 urothelial carcinoma of bladder (UCB) after radical cystectomy (RC).

Radical cystectomy for pT1 urothelial carcinoma of bladder not amenable to TURBT: Long-term results. [10.1016/j.ejso.2019.07.018]


Materials: Data from patients who underwent FDG PET/CT for suspicion of recurrent urothelial carcinoma (UC) between 2007 and 2015 were retrospectively collected in a multicenter study.

18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis—A Multicenter Retrospective Study [10.3390/cancers11050700]


miR-29b expression correlated with low RARβ expression in renal clear cell carcinomas and bladder urothelial carcinomas, tumors associated with TSC gene mutations.

Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ) [10.1038/s41388-019-0957-5]


Third, in human normal urothelial SVHUC cells with exposure to a chemical carcinogen 3-methylcholanthrene (MCA), we assessed the effects of ATF2 knockdown on neoplastic transformation.

MP51-10 ATF2 PROMOTES UROTHELIAL TUMORIGENESIS AND TUMOR PROGRESSION VIA THE ANDROGEN RECEPTOR PATHWAY [10.1097/01.JU.0000556431.71291.40]



Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals